Suppr超能文献

非活性嗜酸乳杆菌预防旅行者腹泻无效:一项随机、双盲、对照研究。

Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study.

作者信息

Briand Valérie, Buffet Pierre, Genty Sabine, Lacombe Karine, Godineau Nadine, Salomon Jérome, Vandemelbrouck Eric, Ralaimazava Pascal, Goujon Catherine, Matheron Sophie, Fontanet Arnaud, Bouchaud Olivier

机构信息

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.

出版信息

Clin Infect Dis. 2006 Nov 1;43(9):1170-5. doi: 10.1086/508178. Epub 2006 Sep 27.

Abstract

BACKGROUND

Diarrhea is the most common illness associated with international tourism. We evaluated the efficacy of a probiotic preparation of nonviable Lactobacillus acidophilus (hereafter referred to as LA) for the prevention of traveler's diarrhea.

METHODS

We conducted a randomized, double-blind, controlled trial. Travelers were randomized to receive either LA or placebo twice daily from 1 day before their departure to 3 days after their return. On each day of the trip and the week following the return, travelers had to record the number and consistency of stools and their adherence to the treatment. Diarrhea was defined as > or =3 unformed stools in a 24-h period.

RESULTS

From January 2001 to September 2004, a total of 174 subjects were randomized to each treatment group. Half of the travelers went to West Africa, and organized tours or backpacking were the most common modes of traveling. The incidence of diarrhea did not differ between the 2 groups; it was 61.4 cases per 100 person-months in the LA group (95% confidence interval [CI], 44.1-85.5) and 43.4 cases per 100 person-months in the placebo group (95% CI, 30.0-62.9) (P=.14). Adjustment for travel duration and other variables did not reveal any difference between the 2 groups (adjusted hazard ratios comparing the LA and placebo groups were 1.43 [95% CI, 0.87-2.36] in an intent-to-treat analysis and 1.38 [95% CI, 0.79-2.39] in an efficacy analysis).

CONCLUSIONS

There was no beneficial effect of treatment with LA for the prevention of travelers' diarrhea. More studies are required to assess the efficacy of other specific probiotics (e.g., a Lactobacillus rhamnosus GG preparation) for preventing traveler's diarrhea.

摘要

背景

腹泻是与国际旅行相关的最常见疾病。我们评估了一种非活性嗜酸乳杆菌益生菌制剂(以下简称LA)预防旅行者腹泻的疗效。

方法

我们进行了一项随机、双盲、对照试验。旅行者被随机分为两组,从出发前1天至返回后3天,每天两次分别服用LA或安慰剂。在旅行的每一天以及返回后的一周内,旅行者必须记录粪便的数量、性状以及他们对治疗的依从性。腹泻定义为24小时内有≥3次不成形粪便。

结果

从2001年1月至2004年9月,共有174名受试者被随机分配至各治疗组。一半的旅行者前往西非,有组织的旅行团或背包旅行是最常见的旅行方式。两组之间腹泻的发生率没有差异;LA组每100人月腹泻发生率为61.4例(95%置信区间[CI],44.1 - 85.5),安慰剂组为每100人月43.4例(95% CI,30.0 - 62.9)(P = 0.14)。对旅行时长和其他变量进行调整后,两组之间未发现任何差异(在意向性分析中,LA组与安慰剂组比较的调整后风险比为1.43 [95% CI,0.87 - 2.36],在疗效分析中为1.38 [95% CI,0.79 - 2.39])。

结论

LA治疗对预防旅行者腹泻没有有益效果。需要更多研究来评估其他特定益生菌(如鼠李糖乳杆菌GG制剂)预防旅行者腹泻的疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验